We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Biomarker Protein Correlates with Severity of Brain Damage in Stroke Patients

By LabMedica International staff writers
Posted on 23 Nov 2020
Researchers have identified a stroke-related biomarker protein that correlates with the severity of brain tissue damage as well as with functional outcome and mortality.

The outcome of a stroke varies greatly between patients from temporary mild symptoms to permanent disability and death. More...
As the currently used clinical scale for measuring disease severity shows poor correlation with brain tissue damage, it is necessary to identify better markers of tissue damage, which could improve the ability to predict outcome and promote the development of better therapies.

In this regard, investigators at the Mayo Clinic (Jacksonville, FL, USA) examined whether the blood protein neurofilament light (NFL) would fulfill this purpose for stroke patients with acute cerebral infarction (ACI), aneurysmal subarachnoid hemorrhage (SAH), or nontraumatic intracerebral hemorrhage (ICH).

Neurofilament light (NFL) is a neurofilament protein that in humans is encoded by the NEFL gene. NFL is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.

For the current study, the investigators measured NFL concentrations in blood collected from 314 stroke patients and in blood from 79 healthy individuals. Results revealed that compared to healthy individuals NFL was higher for all stroke types. NFL associated with radiographic markers of brain tissue damage and correlated with the extent of early ischemic injury in patients with ACI, hemorrhage severity in patients with SAH, and intracranial hemorrhage volume in patients with ICH. Furthermore, higher NFL concentrations independently associated with three- or six-month functional disability and higher all-cause mortality.

"We discovered that blood levels of NFL do predict stroke severity," said senior author Dr. Leonard Petrucelli, professor of neuroscience at the Mayo Clinic. "We found that higher NFL levels forecast worse functional outcomes and shorter survival time after a stroke. We found this to be the case for ischemic stroke and hemorrhagic strokes. Our study establishes NFL as a promising prognostic biomarker for stroke."

The study was published in the November 11, 2020, online edition of the journal Science Translational Medicine.

Related Links:
Mayo Clinic


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.